



IN THE CLAIMS

1. (previously amended) A method for the prevention and treatment of incidental or post-surgical trauma pathologies of the anterior chamber of the eye comprising administering to a patient, via topical ophthalmic application, a collyrium medicament comprising coenzyme ubiquinone Q10.
2. (previously amended) The method according to claim 1, wherein the prevention and treatment of incidental or post-surgical trauma comprises prevention and treatment of corneal haze following corneal trauma, general surgery and refractive surgery; prevention of regression of corrective effects after operation of refractive surgery performed by conventional surgery or by laser radiation; and eye protection against damage determined by solar light and ultraviolet radiation.
3. (previously amended) The method according to claim 2, wherein the prevention and treatment of incidental or post-surgical trauma is directed to protect eye cells against reversible or irreversible damage induced by said surgical operation and/or laser and by exposure to solar and ultraviolet radiation.
4. (previously amended) The method according to claim 3, wherein said irreversible damage of said cells is apoptosis.
5. (previously amended) The method according to claim 4, wherein said cells are corneal stromal keratocytes.
6. (previously amended) The method according to claim 5, wherein said refractive surgery is the photorefractive keratectomy (pRK) and the laser-assisted in situ keratomileusis (LASIK).

7. (previously amended) The method according to claim 6, wherein said photorefractive keratectomy (pRK) and said laser-assisted in situ keratomileusis (LASIK) are performed by laser sources.
8. (previously amended) The method according to claim 7, wherein said laser sources are excimer laser.
- 9 (previously amended) The method according to claim 8, wherein said laser source is a 193 nm ArF excimer laser.
10. (previously amended) The method according to claim 3, wherein said medicament is administered to the patient via topical ophthalmic application to the cornea and wherein said medicament comprises a composition including ubiquinone Q10 in a quantity effective to said treatment and a pharmaceutically compatible vehicle.
11. (previously amended) The method according to claim 10, wherein said vehicle is an aqueous solution of a mixture comprising: a block copolymer of hydrophilic ethylene oxide and lipophilic propylene oxide, having a prevailing proportion of polyoxyethylene, an average molecular weight between 10,000 and 13,000 Dalton and a HLB value higher than 15; and a polyoxyethylene-modified castor oil.
12. (previously amended) The method according to claim 11, wherein said copolymer comprises about 70% of polyoxyethylene and has a HLB value of about 22.0
13. (previously amended) The method according to claim 11 or 12, wherein said polyoxyethylene-modified castor oil is polyethylene glycol glyceryl-triricinoleate.
- 14-24. (canceled)